Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
(Reuters) -Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and plans to increase production of its weight-loss treatment Zepbound and related diabetes drug ...
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing ...
Eli Lilly (LLY) has reported a better-than-expected first-quarter profit and raised its forward guidance as sales of its popular weight-loss drugs accelerate. The pharmaceutical giant reported ...
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its ...
Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
Eli Lilly-Results FILE - A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. Rapidly climbing sales of the new obesity drug Zepbound and its ...